Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension

C. Siegel, S. Danese,D. T. Rubin, J. Sabino, M. D. Long,R. K. Cross,A. Armuzzi, I. Blumenstein, T. Kobayashi, S. Lama,L. Charles, V. Cetin,A. Petersen, H. Wu, D. Wang, A. Jain,G. D'Haens

JOURNAL OF CROHNS & COLITIS(2024)

引用 0|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要